In advance of the long-awaited Dobbs decision, which repealed Roe v. Wade, Reed Smith’s Life Sciences Health Industry Group has started analyzing – and advising on – the legal impact this decision will have on health care providers, pharmacies, manufacturers, insurers, distributors, and other industry entities. While there are currently more questions than answers, such a reversal will have profound implications on a wide range of issues, including private rights of action, physician or pharmacist practice acts, licensing considerations, coverage by payors, and possible criminal or civil implications associated with dispensing certain medications or providing health care services, particularly in some states.

Our team is also examining how this decision at the federal level will trigger changes to many state laws, which will require clients with national or multi-state operations to comply with numerous conflicting laws and regulations.

Other Topics